Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DEA on ’08 PSE needs

This article was originally published in The Tan Sheet

Executive Summary

The Drug Enforcement Agency seeks comments on its proposed revised assessment of 2008 annual U.S. needs of ephedrine, pseudoephedrine and phenylpropanolamine in a June 23 Federal Register notice. It will accept comments through July 23. DEA did not change the original projection assessment, with the proposed medical, scientific, research and production needs of ephedrine (for sale) estimated at 11,500 kg, pseudoephedrine (for sale) at 511,100 kg and phenylpropanolamine (for sale) at 5,545 kg. The projections are based on 2007 year-end inventory and disposition data from quota recipients. An interim final rule to apply the Combat Meth Act requires firms that use the substances to apply by each April 1 for the next year's manufacturing quotas ("1The Tan Sheet" July 16, 2007, p. 8)...

You may also be interested in...

Combat Meth Pseudoephedrine Manufacturing Quota Rule Effective – DEA

Firms using ephedrine, pseudoephedrine, and phenylpropanolamine in drug products must apply by April 1 each year for the following year's manufacturing quotas, under a July 10 interim final rule to implement the Combat Meth Act

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts